SCHEMBL3114411

SCHEMBL3114411

COc1ccc([N+](=O)[O-])cc1Sc1nc2c(N)ncnc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.44
HTT P42858 1/20 0.42
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
AMY1A P0DUB6 1/20 0.38
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
ERBB2 P04626 1/20 0.38
LCK P06239 1/20 0.37
MAPT P10636 2/20 0.37
ALDH1A1 P00352 1/20 0.37
RECQL P46063 1/20 0.37
DUSP3 P51452 1/20 0.37
PTPN5 P54829 1/20 0.37
PTPN11 Q06124 1/20 0.37
BACE1 P56817 1/20 0.37
ENPP1 P22413 1/20 0.37
ABCG2 Q9UNQ0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3122005 0.84 ERBB2 (0.45) TDP1KMT2ALMNAHSP90AA1HSP90AB1
SCHEMBL3127628 0.82 ERBB2 (0.41) TDP1HTTMEN1KMT2ASMN1; SMN2
SCHEMBL1966212 0.82 ERBB2 (0.53) HSP90AA1HSP90AB1ERBB2
SCHEMBL14384475 0.80 ENPP1 (0.43) HSP90AA1HSP90AB1ERBB2RECQLENPP1
SCHEMBL3125506 0.79 HSP90AA1 (0.39) HSP90AA1HSP90AB1ERBB2ENPP1PDE5A
SCHEMBL3126835 0.78 HSP90AA1 (0.44) LMNAHSP90AA1HSP90AB1ERBB2ENPP1
SCHEMBL3111577 0.76 HSP90B1 (0.50) HSP90AA1HSP90AB1ERBB2
SCHEMBL3124057 0.75 HSP90AA1 (0.38) HSP90AA1HSP90AB1ERBB2ENPP1PDE5A
SCHEMBL5044947 0.73 ERBB2 (0.37) HSP90AA1HSP90AB1ERBB2ENPP1PDE5A
SCHEMBL16486867 0.73 PDE7A (0.50) HTTMEN1KMT2ALMNAHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8476285-B2 Purine-core inhibitors of HSP90 and their use in treating cancer MYREXIS, INC. (US) 2013-07-02 US disclosed
US-8476285-B2 Purine-core inhibitors of HSP90 and their use in treating cancer MYREXIS, INC. (US) 2013-07-02 US disclosed
US-20100016586-A1 THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER MYRIAD GENETICS, INCORPORATED (US) 2010-01-21 US disclosed
US-20100016586-A1 THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER MYRIAD GENETICS, INCORPORATED (US) 2010-01-21 US disclosed
US-7595401-B2 Therapeutic compounds and their use in cancer MYRIAD PHARMACEUTICALS, INC. (US) 2009-09-29 US disclosed
US-7595401-B2 Therapeutic compounds and their use in cancer MYRIAD PHARMACEUTICALS, INC. (US) 2009-09-29 US disclosed
US-20070299258-A1 THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER MYRIAD GENETICS, INCORPORATED (US) 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299258-A1 THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER MCL1, TP53, TUBB3 TDP1 3355/4885HTT 2370/4885MEN1 1604/4885
US-20100016586-A1 THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER MCL1, TP53, TUBB3 TDP1 3355/4885HTT 2370/4885MEN1 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.